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The aged are an extremely heterogeneous population
that is growing worldwide. Included are healthy and
agile individuals in their early sixties, as well as an
increasing number of people over the age of 85. Phar-
macotherapy is expected to continue its prominent role
in the medical management of a wide range of condi-
tions that affect older people. Adverse consequences of
all kinds complicate the use of medications, and such
events seem to increase in incidence with polypharmacy.
Cognitive impairment can occur during the course of
treatment with a wide range of medications and can
have a variety of presentations. Both the number of con-
current medications that older individuals routinely use
and physiologic changes in these patients render them
more susceptible to developing cognitive toxicity. Most
of the frequently implicated medications carry docu-
mentation of their ability to cause cognitive disturbances
in their package labeling, suggesting that the level of
vigilance for adverse effects during the course of their
use should always be high. Such caution can be used to
guide appropriate drug treatment of the aged so that
clinicians do not need to opt for undertreatment to
avoid toxicity.
prominent feature of the current and pro-
jected populations in developed and developing coun-
tries is the increase in the relative and absolute num-
bers of aging individuals (Figure 1).
1 Defined by various
organizations as those over age 60, or alternatively 65,
this heterogeneous population is estimated by the World
Health Organization to increase to over one billion
worldwide by the year 2020.
2 Europe is expected to
increase its percentage of aged residents from its cur-
rent 20% to 25%.The population of Japan is expected to
be over 30% aged.Projections for North America,East
Asia, Latin America, and South Asia are 23%, 17%,
12%, and 10%, respectively.
2 The most rapid increases
are expected in developing countries. Whereas France
increased its aged population from 7% to 17% over the
course of 115 years (1865-1980),estimates are that China
will double its number in the same demographic group
from 10% to 20% in the 20 years between 2000 and
2027.
2 Causes of death in developing countries are
expected to be largely age-related by 2020,coming from
noncommunicable diseases such as cancer,diabetes,and
cardiovascular disease,
2 conditions which have been
heavily dependent on drug therapy for management in
developed countries.
In addition, the number of individuals over age 85 will
rise dramatically.The US government expects these “old-
est of the old” to grow by 56% to 5.7 million between
1995 and 2010, as compared with the 13% increase in
those aged 65 to 84.
3 Projections are that the cumulative
growth rate for this particular “oldest”subset from 1995
to 2050 will be greater than 400%, constituting nearly
5% of the total US population.
3 In both the old and old-
est groups, the majority are female. In 1995, there were
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Pharmacological aspectsmore than two times as many women as men in the US
age 85 and over group.
3 Women are expected to con-
tinue to outnumber men in all age categories.Data from
the United Nations
4 show that the life expectancy for
women is greater in virtually all developed and devel-
oping countries, suggesting that most elderly popula-
tions will have some degree of female majority.
Medications are an integral part of the clinical manage-
ment of the health problems of older individuals. In
developed countries, drugs from virtually every thera-
peutic class, including antibiotics, cardiovascular, psy-
chotropics,and antiinflammatory drugs,are used exten-
sively and often in combination in this group of patients,
even though historically almost none of the drug devel-
opment data have been collected in this demographic
group.In a five-country survey including Australia,New
Zealand,Canada,United Kingdom,and the US,approx-
imately 75% of those over the age of 65 in all five coun-
tries took at least one prescription drug on a regular and
ongoing basis for a chronic medical condition.
5 Many
investigators have documented the prevalence of
polypharmacy in populations of similar demographics.
6-8
One group estimates that,although the aged were 13%
of the US population in 1998,they received 34% of dis-
pensed prescription drugs, and the average number of
prescriptions filled per year for an older person was
expected to reach 28.5 in the year 2000.
8 In addition,
older individuals also use nonprescription medications,
including herbal and nutritional supplements.
9-12
Although drug therapy has contributed significantly to
the management of numerous medical conditions in older
patients, a substantial number of these individuals will
experience some sort of adverse drug reaction (ADR).
13-15
ADRs have been recognized as a serious health prob-
lem,and one US government report estimated that 10%
to 15% of geriatric hospital admissions were caused by
ADRs.
16 Other data also support this.
17,18 Documentation
and classification of these events has been hampered by a
lack of common terminology and agreed-upon defini-
tions.In a recent address before a US Senate Committee
on adverse drug events, the Director of the Center for
Drug Evaluation and Research of the Food and Drug
Administration stated that the term “adverse drug reac-
tion” connotes a potential relationship between a med-
ication and an undesired outcome.
19 In addition,she noted
that the overwhelming majority of ADRs reported are
side effects that have already been identified and
described in the product label and can be expected to
occur under certain clinical conditions.Some reports sug-
gest that,although particular drugs are repeatedly impli-
Pharmacological aspects
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Figure 1. Actual and projected demographic data from the US population
1 shown as a representative example of cross-national demographic shifts.
Closed circles connected by solid lines are the actual numbers of individuals aged 65 years or older, with anticipated numbers projected to the
year 2030. In parentheses are the numbers expressed as a percentage of the total population. By 2030, it is expected that 70 million Ameri-
cans will be aged 65 years or older, comprising 20% of the total population.
Reproduced from reference 1: Profile of older Americans: 2000. Washington, DC: Administration on Aging. June 2001. www.aoa.dhhs.gov/aoa/stats/profile/.
Copyright © 2001, Administration on Aging.183
cated in ADRs among older patients,they continue to be
used in ways which are problematic.
20 Overall, the most
important indicator of risk for an ADR has consistently
been shown to be the number of medications a given indi-
vidual takes.
13 The relative odds of an ADR specifically
related to cognitive impairment in older individuals have
also been found to increase as the number of prescription
drugs increased.
21 Whether age itself is an independent
predictor of risk of ADRs in general has been difficult
to assess. Prospective studies conducted by the Gruppo
Italiano di Farmacovigilanza nell’Anziano (GIFA) sug-
gest that age may be an independent risk factor only in
the most advanced age-groups.
17
Cognitive impairment is a broadly definable ADR,which
is extremely important in older people and one to which
they seem to have heightened susceptibility.Symptomatol-
ogy includes disorders that can be termed “psychiatric”
and/or “neurologic,” and often occurs on a continuum.
Some drugs that are linked with discretely classifiable
outcomes,such as depression and suicide or seizures,are
often also noted to cause a variety of more subtle central
nervous system (CNS) disturbances as well,such as con-
fusion or decreased sensorium.Such symptoms are more
difficult to assess and could clearly have an impact on
cognitive abilities. However, these drugs may more rou-
tinely be considered in the context of their most dramatic
adverse sequelae, and may be overlooked when consid-
ering drugs that can impair “cognition.”
Many manifestations of cognitive toxicity can be con-
sidered, from overt delirium and dementia to potential
consequences, such as falls and automobile accidents.
Even the more subtle manifestations, which could
involve mood or memory, can have dramatic conse-
quences if the ability of the individual to perform the
activities necessary for independent living is compro-
mised.The definition of toxicity may be somewhat arbi-
trary and difficult to differentiate categorically from
expected clinical effect. Drugs used for sedation, for
example,may impair cognition in the course of exerting
their therapeutic effect without an undesired outcome if
the setting is proper and the effect terminates in a pre-
dictable and expected manner. That same impairment
in other contexts, however, may lead to serious adverse
consequences and be regarded as toxicity.
As noted above, the fact that aged individuals are com-
monly on multiple medications increases the risk of all
ADRs,
13,14 including those resulting in impaired cogni-
tion. Many of the commonly used medications, such as
digoxin, psychotropics, and those with anticholinergic
(muscarinic-blocking) properties, have been well docu-
mented as causes of cognitive disturbances, even when
used alone.
13,14,22-24A number of intrinsic physiologic alter-
ations also put older individuals at increased risk for cog-
nitive toxicity, including changes in neuroplasticity with
resulting changes in drug sensitivity,
25-27 and changes in
drug distribution and elimination with subsequent phar-
macokinetic toxicity.
28-40 These factors form the basis for
the aged’s increased risk for the development of cognitive
problems from medications.
Manifestations of cognitive toxicity
As with many ADRs, a clear association between drug
and cognitive disturbance can be difficult to definitively
establish, particularly if the disturbance is subtle and if
the impairment is in fact multifactorial in origin.
41,42
Acute confusional states (delirium) have been most
clearly documented by clinical report,but dementia has
also been shown to be a presentation of drug toxicity.
Delirium is characterized by disturbed consciousness
with reduced ability to focus, sustain, or shift atten-
tion.
43,44 Onset is usually rapid with fluctuations in levels
of impairment over the course of a day. Such patients
also frequently exhibit confusion, agitation, delusions,
and/or hallucinations. Many medications have been
reported to cause delirium, such as those with anti-
cholinergic activity, as well as opioids, sedatives, anxi-
olytics,and others.It is also important to recall that with-
drawal from some sedative-hypnotics and anxiolytics
has also been reported to precipitate delirium.
Dementia associated with medication use involves mul-
tiple cognitive deficits, including memory impairment
with accompanying deficits in speech,recognition,motor
and sensory ability,or other executive functions (such as
planning, organizing, or abstracting).
43,44 Onset is gener-
ally insidious, and progression is slow. Drug treatment
may not be ongoing at the time the condition is identi-
fied,but,in general,has previously been prolonged and
intensive. Sedative-hypnotics, anxiolytics, anticonvul-
sants, and intrathecal methotrexate have all been
reported to cause dementia.
Investigators examining the effect of particular drugs in
controlled settings are able to assess less global or drastic,
but still definitive effects by using formal testing to mea-
sure effects on memory, attention/concentration, reac-
tion time, and executive function in relation to drug
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exposure.
45 For example, impairment of mental skills in
older subjects has been found to be greater and more
persistent than in younger subjects following adminis-
tration of some benzodiazepines, such as triazolam and
alprazolam.
46,47 Some data suggest that the aged are more
sensitive to the effects of any given plasma level of these
drugs. Similarly, cognitive decrements have been mea-
sured following oxybutynin and diphenhydramine.
48
These deficits can be assessed using various methods,
such as arithmetic calculation, digit recognition, simple
reaction time, and the digit symbol substitution test.
Although clearly showing cognitive impairment, these
individuals do not have the more dramatic level of symp-
tomatology seen in drug-induced delirium.
Whether or not drug-induced impairment may have a
role in falls or other accidents is less certain.
49-52 Although
falls in older persons are most often multifactorial in ori-
gin,many psychotropic medications,including some with-
out any known propensity for causing orthosta-
tic hypotension, have been consistently linked to an
increased risk of falling and, by some, to overall mortal-
ity.
53 Sedating drugs can clearly impair awareness of haz-
ards and diminish reaction time,and overall sedation and
reaction time have been recognized as two potentially
important factors in falls.Some investigators have found
that a history of a recent fall was independently associated
with involvement in an automobile crash,suggesting that
both incidents could share risk factors.
54A number of ret-
rospective and epidemiologic studies have found that
older drivers who used opioid analgesics and cyclic anti-
depressants had an increased risk for injurious motor
vehicle collisions without any evidence of dose-related
effects.
55 Conflicting results have been found for the ben-
zodiazepines,with some investigators finding that the risk
of crash involvement is increased, while others finding
that it is not.
55-57
While it remains uncertain as to what degree drug-induced
cognitive toxicity is involved in such discretely definable
events as accidents,it is clear that the spectrum of cognitive
impairment ranges from the more obvious presentations
of delirium to the less discernible deficits that can occur in
reaction time,computational skill,symbol recognition,and
memory.The latter may only be considered or identified
outside formal clinical investigations when dramatic
sequelae, such as a fall, occur. In addition, affective or
behavioral toxicity may occur with manifestations such as
depression or agitation.It is possible that these less severe
cognitive manifestations also have a potentially substan-
tial, though undoubtedly variable, effect on activities of
daily living and quality of life. Such consequences, how-
ever, are difficult to measure and even more difficult to
relate to experimental tests of performance.
Risk factors for developing drug-induced 
cognitive impairment
As noted above,the risk of drug-related cognitive toxicity
increases with the number of medications prescribed,and
many older persons concurrently take numerous drugs
as part of their medical regimens.However,there are also
factors that are intrinsic to aging individuals that increase
the likelihood of undesirable cognitive side effects.There
is evidence that both neurotransmission and signal trans-
duction undergo changes during aging,leading to changes
in regulation,sensitivity,and efficiency of the entire neu-
rotransmission process.
25-27 Data suggest that there is prob-
able reduced transmission in many systems,including the
cholinergic, GABAergic (GABA, γ -aminobutyric acid),
serotonergic,dopaminergic,and noradrenergic systems.
58
Some data indicate that this may be due to loss of neurons
or synapses, while other data indicate that there is neu-
ronal dysfunction.
25,26 Loss of proteins that regulate synap-
tic plasticity has been documented both in the normal
aging brain and in Alzheimer’s disease.
27 Such alterations
may render the older individual more vulnerable to drugs
that further perturb these systems. An anticholinergic
drug administered to an aged person,for example,blocks
postsynaptic acetylcholine receptors in a CNS that
already has compromised cholinergic system activity.The
result can be confusion,disorientation,and memory loss,
which would not occur in a younger person with more
baseline acetylcholine neurotransmission.
Other fundamental changes that occur outside the CNS
also increase the vulnerability of aging people to cognitive
toxicity.Older individuals,especially the oldest of the old,
have changes in the way they distribute and clear drugs,
which can lead to altered pharmacokinetics and, ulti-
mately,pharmacodynamics.
28The most important involves
the capacity to remove drugs from the body. Clearance
(intrinsic to organ function) and dosing (controlled by
the clinician) will determine the amount of drug accumu-
lation in the body as well as contribute to the determina-
tion of elimination half-life. For drugs that cross the
blood–brain barrier, higher plasma levels will lead to
higher CNS drug concentrations with the accompanying
risk of toxicity. Identical dosing regimens given to older
Pharmacological aspects185
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Figure 2. Consequences of reduced clearance in the elderly. For any given
drug, impairment of the capacity for drug elimination (reduced
clearance) will cause an elevation in steady-state concentrations
(Css) with a resulting increase in the likelihood of toxicity.
Reduced clearance also may cause a prolongation of elimination
half-life, and a consequent delay in the rate of attainment of the
steady-state condition. An increase in volume of distribution (Vd)
may also contribute to a prolongation of elimination half-life.
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Figure 3. Mean (±SE) plasma chlordiazepoxide concentrations in a series of young and elderly male volunteers who received a single 50-mg intravenous
dose of chlordiazepoxide hydrochloride.
59 Note the slower elimination of chlordiazepoxide in the elderly group.
and younger patients will result in different concentra-
tions at steady state if clearance rates differ (Figure 2).
As age increases, renal blood flow and glomerular filtra-
tion rate decrease, and drugs eliminated by the kidneys
generally exhibit reduced clearance.Similarly,a number of
drugs cleared in the liver by oxidative metabolism also
show reduced clearance because of reductions in enzy-
matic activity (Figures 3 and 4).
59 One particularly impor-
tant route of hepatic clearance involves metabolism by
cytochrome P450-3A4 (CYP3A4).This enzyme is found in
the liver and small intestine and is solely or significantly
involved in the clearance of the majority of drugs in clini-
cal use today.Examples of psychoactive drugs that utilize
this pathway to some important degree include alprazo-
lam,diazepam,triazolam,zolpidem,citalopram,amitripty-
line, nefazodone, trazodone, and haloperidol. Most have
been found to have impaired clearance in aging popula-
tions.
28 Though drug transport proteins, such as P-glyco-
protein, the multidrug resistant (mdr1) gene product, are
increasingly identified as being importantly involved in
the distribution and clearance of many drugs, such as
digoxin,virtually nothing is known about the effect of nor-
mal aging on their expression or function.
60,61 Further
examination of their behavior in the intestine,liver,kidney,
and blood–brain barrier may be important in explaining
both kinetic and dynamic sensitivity in older people.In addition to changes in specific organs,such as the kid-
ney and the liver,more general changes in body habitus
also take place.There is an overall increase in adipose tis-
sue, which leads to an increased volume of distribution
for lipophilic drugs.Gender is an important factor,since
women have a greater proportion of adipose tissue than
men, regardless of age. Such changes do not affect
absolute drug accumulation, but they do affect elimina-
tion half-life, which means that the time until a steady-
state situation is reached will be increased.Consequently,
the time from the initiation of drug therapy or dosage
change until the plasma levels have arrived at the new
higher (or lower) steady-state will be prolonged.Time to
desired clinical effect can also be expected to be pro-
longed. Furthermore, when a given medication effect
(such as a sign of toxicity) occurs later than expected, it
may lead to the erroneous conclusion that it is not med-
ication-related,since the patient was already considered
(erroneously) to be “stabilized”on a particular medica-
tion.Given that the majority of the aged are female,sub-
stantial differences in volumes of distribution can be
expected. For drugs whose initial pharmacokinetic pro-
files have been determined in younger, predominantly
male populations,
62 the differences between actual and
expected half-lives could be striking.For lipophilic drugs
that require renal excretion or hepatic oxidation, the
combination of reduced clearance and increased volume
of distribution will lead to profound increases in half-
life. The familiar adage, “start low, go slow,” suggesting
lower starting doses with slower and smaller incremental
changes,becomes almost a clinical imperative.
Frequently implicated medications
A number of medications seem to have a predictable
potential for causing cognitive toxicity in aging individu-
als. Often this information is clearly presented in the
drug’s product labeling.
63This should not be misconstrued
to mean that these medications are never appropriate
for use in aging people. Close management with consid-
eration of the specific patient and clinical circumstances
and particular risk–benefit balance may result in efficacy
with minimal or acceptable side effects.Generally,drugs
that are predominantly used in older populations will
reveal any toxicities in that same population. It may not
be clear whether older individuals are at greater risk.
Medications that are used in all age-groups seem to be
more likely to have been studied with regard to whether
the elderly are more likely to develop these toxicities.
Further,there are medications not individually discussed
that are sporadically linked with toxic effects.As exam-
ples,nonsteroidal antiinflammatory drugs and histamine
receptor antagonists are both widely used in their pre-
scription and over-the-counter forms. Both are occa-
sionally mentioned as causes of confusion. For some
medications,conflicting data exist regarding whether the
Pharmacological aspects
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Figure 4. Mean (±SE) values of chlordiazepoxide elimination half-life (left) and clearance (right) in young and elderly male volunteers as determined in
the study described in Figure 3.
59 The asterisk (*) indicates a statistically significant difference between young and elderly groups.Cognitive toxicity of drugs in the elderly - von Moltke et al Dialogues in Clinical Neuroscience - Vol 3 . No.3 . 2001
187
medication itself can be independently implicated in
causing cognitive impairment (eg, histamine receptor
antagonists)
64 or whether the elderly are more sensitive
to a particular undesirable effect (eg,alprazolam).
65
Some medications may indirectly participate in causing
cognitive difficulties by impairing normal excretion of a
drug with CNS effects.
66 Such drug interactions are most
common with the very potent inhibitors of drug metabo-
lism (eg,ketoconazole inhibition of CYP3A4).
67The same
may prove to be true of inhibition of drug transport. For
herbal and other dietary supplements, there are few data
available to make any kind of assessment. In spite of
assigned “likelihood”for causing undesirable CNS effects,
any change in cognitive function that occurs during the
course of any drug or “health aid” therapy should imme-
diately prompt the consideration that medication or sup-
plements may be involved.This is particularly true for the
frail elderly and those hospitalized in critical care settings.
Medications with anticholinergic characteristics
These medications can cause a wide range of symptoma-
tology ranging from deficits in attention and memory to
florid delirium. Anticholinergic activity can be found in
drugs across many therapeutic classes.Scopolamine is used
to model the memory deficits found in Alzheimer’s dis-
ease.
68Atropine and scopolamine can cause delirium even
in low doses and when used as mydriatics.
22 Oxybutynin,
cyclobenzaprine,diphenhydramine,trihexyphenidyl,ben-
ztropine, doxepin, amitriptyline, clomipramine, trim-
ipramine, imipramine, protriptyline, clozapine, chlorpro-
mazine,chlorprothixene,and thiothixene are just some of
the drugs that possess significant anticholinergic activity.
63
Psychotropic characteristics of some of the above,such as
the tricyclic antidepressants and neuroleptics,may be addi-
tive with the anticholinergic properties in causing unde-
sirable symptomatology. It should be noted that proper
drug treatment of geriatric depression has been shown to
improve cognitive abilities even when accompanied by
slight increases in serum anticholinergicity.
69
Sedative-hypnotics
A variety of effects are detectable and vary with the use
pattern and particular drug.Some “toxicity”can be viewed
as an extension of therapeutic effect.The benzodiazepines
have received extensive study.
28,37,38 Following acute and
chronic benzodiazepine administration, aged individuals
may achieve higher plasma levels,with consequently more
pronounced sedation and performance impairment. In
addition, the aged may exhibit increased sensitivity to
some benzodiazepines.Data have linked long-acting ben-
zodiazepines with an increased risk of falls, while other
investigations suggest that dosing has a greater effect than
duration of drug action. Withdrawal has been accompa-
nied by delirium.In settings of single-dose administration,
such as for insomnia or discrete anxiety episodes, appro-
priate drug choice and dosing can virtually ensure that
drug effect and its associated impairment will terminate at
a reasonably predictable time. Simply substituting highly
anticholinergic drugs or older, less studied medications
such as meprobamate
68,70 in place of benzodiazepines will
not in itself reduce the risk of cognitive toxicity.
Other medications
The following drugs or drug classes have been implicated
in the concurrence of cognitive toxicity.
• Selegiline. The most frequent problems include delir-
ium,hallucinations,agitation,and overall sedation.
71
• L-dopa. Used as a sole agent or in combination with
carbidopa, a variety of cognitive problems have been
reported to be associated with its use.
72,73
• Amantadine. Used as an antiviral as well as in Parkin-
son’s disease, therapy has been linked to suicide
attempts in patients with and without previous psychi-
atric problems. These patients exhibit a variety of
abnormal mental states, including confusion, depres-
sion, paranoia, personality changes, and aggressive
behavior.
74,75 In aging populations, where its use would
most likely occur,clearance is reduced and plasma lev-
els are higher at standard doses.
• Phenytoin.The CNS is the most common site of toxic-
ity, which appears to be dose-related, but can occur
even within the usual effective serum concentration
range of 40 to 79 µmol/L. Confusion as well as speech
and coordination difficulties are common.
76
• Digoxin.Some data indicate that this drug ranks first in
the number of prescriptions made out to the elderly in
the US.
77A spectrum of CNS-related effects can occur,
including depression and anxiety as well as confusion
and delirium with hallucinations. Such symptoms may
appear in the absence of cardiac toxicity and at thera-
peutic plasma levels (0.6–2.6 nmol/L).
78 Clearance of
digoxin correlates with renal function as determined by
creatinine clearance,which generally declines with age.Pharmacological aspects
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•  -Blockers. Symptoms ranging from depression to
memory disturbances and pseudodementia have been
attributed to individual drugs, including propranolol
and local use of timolol in glaucoma.
79,80
• Lidocaine. Symptoms ranging from confusion to delir-
ium are common manifestations of toxicity.
81
• Antibiotics. Penicillins, cephalosporins, quinolones, and
imipenem/cilastatin have all been shown to cause cogni-
tive disturbances,particularly at high doses in renal insuf-
ficiency, severely ill patients, and/or patients with
increased blood–brain barrier permeability.Quinolones
such as ciprofloxacin can cause events such as anxiety
and agitation,while imipenem can precipitate confusion
(as well as convulsions).
82-89
• Corticosteroids. Particularly at higher doses,drugs such
as prednisone can precipitate psychosis. Memory and
attention deficits have also occurred during chronic
therapy.
87,88
• Immunochemotherapy.Both interferon-alpha and inter-
leukin-2 have been linked with serious depression.
89,90
• Opiate analgesic. Symptoms ranging from overt seda-
tion to depression and delirium have occurred with
many of the narcotics and vary with the clinical setting
(postoperative vs chronic pain management). Some
investigators feel that meperidine may be more likely
to cause symptoms because of the anticholinergic
nature of its metabolite, normeperidine.
91,92 However,
all opiate agonists have anticholinergic effects,which in
turn may precipitate delirium. Long-term codeine use
has been associated with depressive symptoms.
93
Comment
As clinicians in adult medicine settings worldwide see
an increasingly aging patient population, it will be nec-
essary to remain abreast of which medications or health
aids, both prescription and nonprescription, can cause
disorders of cognition,as well as to recognize the variety
of presentations. It should not be necessary to under-
treat the elderly and deprive them of the benefits of
pharmacotherapy in order to avoid toxicity.
94A high level
of care and vigilance should keep the therapy that is
intended to extend life and enhance its quality from
diminishing vital cognitive capacity.❑
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Toxicidad cognitiva de fármacos utilizados
en sujetos de edad avanzada
Los ancianos constituyen una población extre-
madamente heterogénea que está creciendo en
todo el mundo. Incluso hay individuos sanos y
ágiles en los inicios de los sesenta como también
un número creciente de personas de edad supe-
rior a los 85 años. Se espera que la farmacotera-
pia continúe su papel destacado en el manejo
médico de una amplia variedad de condiciones
que afectan a la población mayor. Las conse-
cuencias adversas de todo tipo complican el
empleo de medicamentos y tales eventos pare-
cen aumentar su incidencia con la polifarmacia.
El deterioro cognitivo puede ocurrir durante el
curso del tratamiento con una amplia gama de
medicamentos y puede tener una variedad de
presentaciones. Tanto el número de fármacos
combinados que los individuos mayores rutina-
riamente utilizan, como los cambios fisiológicos
en estos pacientes contribuyen a hacerlos más
susceptibles de presentar una toxicidad cogniti-
va. La mayoría de los medicamentos frecuente-
mente implicados en esta toxicidad llevan docu-
mentación acerca de su capacidad para provocar
alteraciones cognitivas rotuladas en el envase,
lo que sugiere que el nivel de vigilancia de estos
efectos durante el curso de su empleo debe ser
siempre alto. Esta preocupación puede tenerse
en cuenta para orientar apropiadamente acerca
del tratamiento con fármacos en el anciano, de
tal forma que los clínicos no necesiten optar por
un subtratamiento para evitar la toxicidad.
Toxicité cognitive des médicaments utilisés
chez les personnes âgées
Les personnes âgées constituent une population
très hétérogène qui augmente dans le monde
entier. Elle comprend aussi bien des individus
alertes et en bonne santé de la soixantaine, qu’un
nombre croissant de personnes dépassant les 85
ans. La pharmacothérapie est appelée à poursuive
son rôle de premier plan dans la prise en charge
médicale de nombre de pathologies touchant les
personnes âgées. Des effets indésirables de toutes
sortes compliquent l’utilisation des médicaments, et
la polymédication semble augmenter leur inci-
dence. Un grand nombre de médicaments peuvent
entraîner l’apparition d’une détérioration cogni-
tive, cette dernière pouvant d’ailleurs se présenter
sous diverses formes. Tant le nombre de médica-
ments différents pris quotidiennement par les
sujets âgés que les modifications physiologiques
inhérentes à l’âge sont responsables, chez ces
patients, d’une susceptibilité particulière au déve-
loppement d’une toxicité cognitive. Les notices de
la plupart des médicaments courants impliqués
signalent la possibilité de l’apparition de troubles
cognitifs, ce qui implique que le niveau de vigi-
lance relatif aux événements indésirables pendant
le traitement doit toujours rester élevé. Cette vigi-
lance permettra aux médecins de prescrire les trai-
tements appropriés chez les sujets âgés plutôt que
de les sous-traiter par peur de l'apparition d'une
toxicité. 
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